Navigation Links
Labopharm announces change to Board of Directors

LAVAL, QC, Nov. 7 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that Rachel R. Selisker has been appointed to the Board of Directors of the Company to fill the vacancy created by the resignation of James S. Scibetta, who has stepped down for personal reasons. Ms. Selisker will also replace Mr. Scibetta as Chairman of the Audit Committee. Ms. Selisker, a Certified Public Accountant, will bring senior financial advisory expertise in the healthcare industry as well as more than 13 years of experience as chief financial officer of a high growth, international pharmaceutical services company.

Santo J. Costa, Chairman of the Board of Directors of Labopharm, said, "Jim has been a positive influence on Labopharm and has made significant contributions to our Board since joining in 2001. We have benefited greatly from his insights and we wish him well in his future endeavours."

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel SARI containing trazodone for the treatment of major depressive disorder is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Labopharm Reports Results for Third Quarter Fiscal 2008
2. Labopharm to host conference call Friday, November 7, 2008 at 8:30 a.m. (ET)
3. Labopharms Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria
4. Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET)
5. FDA accepts Labopharms response for once-daily tramadol as complete Class 2 response
6. Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product
7. Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol
8. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
9. Labopharm Reports Results for First Quarter Fiscal 2008
10. Labopharm announces details for first quarter results conference call and annual meeting
11. Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer
Post Your Comments:
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
Breaking Medicine Technology: